Search details
1.
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
AIDS
; 21(7): 813-23, 2007 Apr 23.
Article
in English
| MEDLINE | ID: mdl-17415036
2.
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
N Engl J Med
; 350(18): 1850-61, 2004 Apr 29.
Article
in English
| MEDLINE | ID: mdl-15115831
3.
Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
J Pharm Biomed Anal
; 44(1): 188-95, 2007 May 09.
Article
in English
| MEDLINE | ID: mdl-17391891
4.
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
JAMA
; 296(7): 769-81, 2006 Aug 16.
Article
in English
| MEDLINE | ID: mdl-16905783
5.
Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens.
Diabetes
; 52(4): 918-25, 2003 Apr.
Article
in English
| MEDLINE | ID: mdl-12663461
6.
Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.
Clin Drug Investig
; 23(5): 323-8, 2003.
Article
in English
| MEDLINE | ID: mdl-17535044
7.
Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.
Biopharm Drug Dispos
; 29(2): 91-101, 2008 Mar.
Article
in English
| MEDLINE | ID: mdl-18041735
8.
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
J Infect Dis
; 198(9): 1345-52, 2008 Nov 01.
Article
in English
| MEDLINE | ID: mdl-18771406
9.
Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.
Metab Syndr Relat Disord
; 5(2): 163-73, 2007 Jun.
Article
in English
| MEDLINE | ID: mdl-18007962
10.
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
Ther Drug Monit
; 29(1): 103-9, 2007 Feb.
Article
in English
| MEDLINE | ID: mdl-17304157
11.
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
Ther Drug Monit
; 29(5): 560-5, 2007 Oct.
Article
in English
| MEDLINE | ID: mdl-17898644
12.
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
Pharmacogenomics
; 8(3): 227-35, 2007 Mar.
Article
in English
| MEDLINE | ID: mdl-17324111
13.
Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.
Antimicrob Agents Chemother
; 51(5): 1822-6, 2007 May.
Article
in English
| MEDLINE | ID: mdl-17283195
14.
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.
Am J Addict
; 16(6): 488-94, 2007.
Article
in English
| MEDLINE | ID: mdl-18058416
15.
Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York.
J Infect Dis
; 194(4): 428-34, 2006 Aug 15.
Article
in English
| MEDLINE | ID: mdl-16845625
16.
Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
Antimicrob Agents Chemother
; 49(8): 3373-81, 2005 Aug.
Article
in English
| MEDLINE | ID: mdl-16048950
17.
Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group.
J Acquir Immune Defic Syndr
; 33(3): 329-35, 2003 Jul 01.
Article
in English
| MEDLINE | ID: mdl-12843743
Results
1 -
17
de 17
1
Next >
>>